Regentis Biomaterials Ltd.
RGNT evidence brief
What we can confirm
- Market Cap:
- $13.3M
What it means
What to watch
Prepared research question
What matters most for RGNT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RGNT
Regentis Biomaterials Ltd. is an Israeli biotech company developing GelrinC, an off-the-shelf regenerative cartilage repair product, currently in a pivotal Phase III clinical trial and preparing for European commercial launch.
Key risk: Pre-revenue stage
Market Cap
$13.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Regentis Biomaterials Ltd. is an Israeli biotech company developing GelrinC, an off-the-shelf regenerative cartilage repair product, currently in a pivotal Phase III clinical trial and preparing for European commercial launch.
- Cash & equivalents of $7.4M and shareholders' equity of $4.7M as of 2025-12-31 [sec].
- Gross proceeds from an offering expected to be approximately $6.5 million, closing on or about June 23, 2026 [sec · filed 2026-06-18].
- Pivotal Phase III clinical trial for GelrinC is ongoing, with expansion of clinical site networks in the U.S. and Europe [sec · filed 2026-01-29] [sec · filed 2026-02-17].
- European regulatory approval received for a new GelrinC manufacturing process that increases production yield by 400% [sec · filed 2026-07-15].
- GelrinC demonstrated long-term durability of cartilage repair via quantitative MOCART evaluation [sec · filed 2026-01-06].
What works
- GelrinC has shown long-term durability of cartilage repair in MRI-based MOCART evaluation, supporting its regenerative potential [sec · filed 2026-01-06].
- European regulatory approval for a new manufacturing process that increases production yield by 400% ahead of commercial launch [sec · filed 2026-07-15].
- Expansion of clinical site networks in both the U.S. and Europe for the pivotal Phase III trial [sec · filed 2026-01-29] [sec · filed 2026-02-17].
- Appointment of a Chief Financial Officer and Chief Business Officer as the company progresses toward commercialization [sec · filed 2026-02-05].
What to weigh
- The company is pre-revenue and relies on external financing; cash & equivalents were $7.4M as of 2025-12-31, with an additional $6.5M offering expected to close in June 2026 [sec] [sec · filed 2026-06-18].
- GelrinC is still in a pivotal Phase III trial, and regulatory approval (FDA PMA submission) has not yet been submitted [sec · filed 2026-06-18].
- The company is a foreign private issuer with limited operational history in the U.S., which may add regulatory and market-entry complexity [sec · filed 2026-09-11].
From the filings
Quoted directly from source documents.
Offering gross proceeds and intended use
“gross proceeds from the Offering are expected to be approximately $6.5 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company. The Offering is expected to close on or about June 23, 2026”
SEC filings · June 18, 2026
European manufacturing approval with 400% yield increase
“Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch”
SEC filings · July 15, 2026
Long-term durability of cartilage repair via MOCART
“Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation”
SEC filings · January 6, 2026
Risks & what to watch (3)›
Key risks
- Pre-revenue stage — Company has no product revenue; relies on cash reserves and new offerings to fund operations [sec].
- Regulatory approval uncertainty — Pivotal Phase III trial ongoing; FDA PMA submission not yet filed; approval not guaranteed [sec · filed 2026-06-18].
- Limited cash runway — Cash of $7.4M as of 2025-12-31 plus $6.5M offering may only support operations for a limited period [sec] [sec · filed 2026-06-18].
What to watch
- Completion of the $6.5M offering expected to close on or about June 23, 2026 [sec · filed 2026-06-18].
- Progress and enrollment updates for the pivotal Phase III GelrinC trial [sec · filed 2026-01-29].
- European commercial launch preparations, including surgeon training and MDR compliance [sec · filed 2026-06-08] [sec · filed 2026-07-15].
- Any filing of the pre-market approval (PMA) submission to the FDA [sec · filed 2026-06-18].
Sources: SEC filings · Generated October 2, 2026 · How we verify sources →
Run Regentis Biomaterials Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Regentis Biomaterials Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$1.7M
| Holder | Shares | Value |
|---|---|---|
| aigh capital management llc | 300,000 | $917K |
| rosalind advisors, inc. | 251,510 | $768K |
| ubs group ag | 334 | $1K |
Short Interest
as of May 22, 2026- % of float
- 0.4%
- Days to cover
- 3.3
- Shares short
- 12,485
- Daily short volume (Jun 2, 2026)
- 56.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGNT short interestFrequently asked questions
What is the AI investment thesis for Regentis Biomaterials Ltd.?
Regentis Biomaterials Ltd. is an Israeli biotech company developing GelrinC, an off-the-shelf regenerative cartilage repair product, currently in a pivotal Phase III clinical trial and preparing for European commercial launch.
Who is the CEO of Regentis Biomaterials Ltd.?
Dr. Ehud Geller Ph.D. is the chief executive officer of Regentis Biomaterials Ltd. (RGNT).
Where is Regentis Biomaterials Ltd. headquartered?
Regentis Biomaterials Ltd. (RGNT) is headquartered in Herzliya, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.